CVS Caremark (NYSE: CVS ) is expected to report Q3 earnings around Nov. 1. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict CVS Caremark's revenues will grow 12.8% and EPS will increase 20.0%.
The average estimate for revenue is $30.09 billion. On the bottom line, the average EPS estimate is $0.84.
Last quarter, CVS Caremark notched revenue of $30.71 billion. GAAP reported sales were 16% higher than the prior-year quarter's $26.41 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.81. GAAP EPS of $0.75 for Q2 were 25% higher than the prior-year quarter's $0.60 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 17.7%, 160 basis points worse than the prior-year quarter. Operating margin was 5.6%, about the same as the prior-year quarter. Net margin was 3.1%, about the same as the prior-year quarter.
The full year's average estimate for revenue is $122.80 billion. The average EPS estimate is $3.37.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,666 members out of 1,730 rating the stock outperform, and 64 members rating it underperform. Among 415 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 404 give CVS Caremark a green thumbs-up, and 11 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on CVS Caremark is outperform, with an average price target of $50.58.
If you're interested in retailers like CVS Caremark as investments, you should check out the retail concept that is The Motley Fool's top stock for 2012. Its founder wrote the book on big box retailing, and it's growing in increasingly important international markets. Click here for instant access to this free report.